Formulation Development Outsourcing Market Size to Garner USD 75.8 Billion by 2032

The global formulation development outsourcing market size was estimated to be around US$ 37.4 billion in 2022. It is projected to reach US$ 75.8 billion by 2032, indicating a CAGR of 7.32% from 2023 to 2032.

Key Takeaways:

• By region, Asia- Pacific contributed more than 41% of revenue share in 2022, the region is anticipated to register the fastest growth rate during the forecast period.
• By service, the formulation development generated over 77% of revenue share in 2022.
• By formulation, the oral segment had the largest market share of 64% in 2022.
• By therapeutic area, the oncology segment carried the largest market share of 26% in 2022, the segment is expected to sustain its position during the forecast period.
• By end-user, the pharmaceutical industry segment is expected to be dominant in the market during the predicted period.

The market research report on the Formulation development outsourcing market provides a comprehensive analysis of various key aspects. It includes the definition, classification, and application of Formulation development outsourcing products. The report examines the development trends, competitive landscape, and industrial chain structure within the industry. Furthermore, it presents an overview of the industry, analyzes national policies and planning, and offers insights into the latest market dynamics and opportunities at a global level.

Get a Sample: https://www.precedenceresearch.com/sample/3192

Formulation Development Outsourcing Market  Report Scope 

Read More: Carbonated Beverage Market Size to Garner USD 654.37 Billion by 2032

The report presents the volume and value-based market size for the base year 2022 and forecasts the market’s growth between 2023 and 2032. It estimates market numbers based on product form and application, providing size and forecast for each application segment in both global and regional markets.

Focusing on the global Formulation development outsourcing market, the report highlights its status, future forecasts, growth opportunities, key market players, and key market regions such as the United States, Europe, and China. The study aims to present the development of the Formulation development outsourcing market by considering factors like Year-on-Year (Y-o-Y) growth, in addition to Compound Annual Growth Rate (CAGR). This approach enables a better understanding of market certainty and the identification of lucrative opportunities.

Regarding production, the report investigates the capacity, production, value, ex-factory price, growth rate, and market share of major manufacturers, regions, and product types. On the consumption side, the report focuses on the regional consumption of Formulation development outsourcing products across different countries and applications.

Buyers of the report gain access to verified market figures, including global market size in terms of revenue and volume. The report provides reliable estimations and calculations for global revenue and volume by product type from 2023 to 2032. It also includes accurate figures for production capacity and production by region during the same period.

The research includes product parameters, production processes, cost structures, and data classified by region, technology, and application. Furthermore, it conducts SWOT analysis and investment feasibility studies for new projects.

This in-depth research report offers valuable insights into the Formulation development outsourcing market. It employs an objective and fair approach to analyze industry trends, supporting customer competition analysis, development planning, and investment decision-making. The project received support and assistance from technicians and marketing personnel across various links in the industry chain.

The competitive landscape section of the report provides detailed information on Formulation development outsourcing market competitors. It includes company overviews, financials, revenue generation, market potential, research and development investments, new market initiatives, global presence, production sites, production capacities, strengths and weaknesses, product launches, product range, and application dominance. However, the data points provided only focus on the companies’ activities related to the Formulation development outsourcing market.

Prominent players in the market are expected to face tough competition from new entrants. Key players are targeting acquisitions of startup companies to maintain their dominance. The report

Reasons to Purchase this Report:

• Comprehensive market segmentation analysis incorporating qualitative and quantitative research, considering the impact of economic and policy factors.
• In-depth regional and country-level analysis, examining the demand and supply dynamics that influence market growth.
• Market size in USD million and volume in million units provided for each segment and sub-segment.
• Detailed competitive landscape, including market share of major players, recent projects, and strategies implemented over the past five years.
• Comprehensive company profiles encompassing product offerings, key financial information, recent developments, SWOT analysis, and employed strategies by major market players.

Key Players

• SGS S.A.
• Eurofins Scientific SE
• Element
• Labcorp
• Thermo Fisher Scientific, Inc. (Patheon)
• Intertek Group plc
• Recipharm
• Lonza
• Charles River Laboratories International, Inc.
• Catalent Inc.

Formulation Development Outsourcing Market Segmentations

By Service

• Preformulation
• Formulation Development

By Formulation

• Topical
• Oral
• Injectable
• Others

By Therapeutic Area

• Oncology
• Infectious Disease
• Respiratory
• Cardiovascular
• Neurology
• Hematology
• Dermatology
• Others

By End-User

• Pharmaceutical Industries
• Research and Academic Institutions

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Formulation Development Outsourcing Market 

5.1. COVID-19 Landscape: Formulation Development Outsourcing Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Formulation Development Outsourcing Market, By Service

8.1. Formulation Development Outsourcing Market, by Service, 2023-2032

8.1.1. Preformulation

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Formulation Development

8.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Formulation Development Outsourcing Market, By Formulation

9.1. Formulation Development Outsourcing Market, by Formulation, 2023-2032

9.1.1. Topical

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Oral

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Injectable

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Others

9.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Formulation Development Outsourcing Market, By Therapeutic Area 

10.1. Formulation Development Outsourcing Market, by Therapeutic Area, 2023-2032

10.1.1. Oncology

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Infectious Disease

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. Respiratory

10.1.3.1. Market Revenue and Forecast (2020-2032)

10.1.4. Cardiovascular

10.1.4.1. Market Revenue and Forecast (2020-2032)

10.1.5. Neurology

10.1.5.1. Market Revenue and Forecast (2020-2032)

10.1.6. Hematology

10.1.6.1. Market Revenue and Forecast (2020-2032)

10.1.7. Dermatology

10.1.7.1. Market Revenue and Forecast (2020-2032)

10.1.8. Others

10.1.8.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Formulation Development Outsourcing Market, By End-User 

11.1. Formulation Development Outsourcing Market, by End-User, 2023-2032

11.1.1. Pharmaceutical Industries

11.1.1.1. Market Revenue and Forecast (2020-2032)

11.1.2. Research and Academic Institutions

11.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 12. Global Formulation Development Outsourcing Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Service (2020-2032)

12.1.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.1.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.1.4. Market Revenue and Forecast, by End-User (2020-2032)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Service (2020-2032)

12.1.5.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.1.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.1.5.4. Market Revenue and Forecast, by End-User (2020-2032)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Service (2020-2032)

12.1.6.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.1.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.1.6.4. Market Revenue and Forecast, by End-User (2020-2032)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Service (2020-2032)

12.2.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.2.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.2.4. Market Revenue and Forecast, by End-User (2020-2032)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Service (2020-2032)

12.2.5.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.2.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.2.5.4. Market Revenue and Forecast, by End-User (2020-2032)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Service (2020-2032)

12.2.6.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.2.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.2.6.4. Market Revenue and Forecast, by End-User (2020-2032)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Service (2020-2032)

12.2.7.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.2.7.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.2.7.4. Market Revenue and Forecast, by End-User (2020-2032)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Service (2020-2032)

12.2.8.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.2.8.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.2.8.4. Market Revenue and Forecast, by End-User (2020-2032)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Service (2020-2032)

12.3.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.3.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.3.4. Market Revenue and Forecast, by End-User (2020-2032)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Service (2020-2032)

12.3.5.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.3.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.3.5.4. Market Revenue and Forecast, by End-User (2020-2032)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Service (2020-2032)

12.3.6.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.3.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.3.6.4. Market Revenue and Forecast, by End-User (2020-2032)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Service (2020-2032)

12.3.7.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.3.7.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.3.7.4. Market Revenue and Forecast, by End-User (2020-2032)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Service (2020-2032)

12.3.8.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.3.8.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.3.8.4. Market Revenue and Forecast, by End-User (2020-2032)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Service (2020-2032)

12.4.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.4.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.4.4. Market Revenue and Forecast, by End-User (2020-2032)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Service (2020-2032)

12.4.5.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.4.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.4.5.4. Market Revenue and Forecast, by End-User (2020-2032)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Service (2020-2032)

12.4.6.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.4.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.4.6.4. Market Revenue and Forecast, by End-User (2020-2032)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Service (2020-2032)

12.4.7.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.4.7.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.4.7.4. Market Revenue and Forecast, by End-User (2020-2032)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Service (2020-2032)

12.4.8.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.4.8.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.4.8.4. Market Revenue and Forecast, by End-User (2020-2032)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Service (2020-2032)

12.5.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.5.4. Market Revenue and Forecast, by End-User (2020-2032)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Service (2020-2032)

12.5.5.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.5.5.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.5.5.4. Market Revenue and Forecast, by End-User (2020-2032)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Service (2020-2032)

12.5.6.2. Market Revenue and Forecast, by Formulation (2020-2032)

12.5.6.3. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

12.5.6.4. Market Revenue and Forecast, by End-User (2020-2032)

Chapter 13. Company Profiles

13.1. SGS S.A.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Eurofins Scientific SE

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Element

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Labcorp

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Thermo Fisher Scientific, Inc. (Patheon)

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Intertek Group plc

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Recipharm

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Lonza

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Charles River Laboratories International, Inc.

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Catalent Inc.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com